Phase 3 Trial Of Immunotherapy With Autologous Antigen Presenting Cells

Principal Investigator: Nancy Dawson, Oncology
Disease Stage: Advanced

A randomized, double blind, placebo controlled phase 3 trial of immunotherapy with autologous antigen presenting cells loaded with pa2024 in asymptomatic subjects with gleason sum < 7, metastatic, androgen independent prostatic adenocarcinomas

This study is for patients with prostate cancer that has spread beyond the prostate and cannot be cured by standard therapy. APC8015 is an investigational immune system treatment for prostate cancer. APC8015 uses activated antigen-presenting cells that are prepared from a patient's own blood cells. These cells are removed from the body, activated with a protein substance in the laboratory, and infused back into the body. Antigen presenting cells are a type of white blood cells and they are important in the immune system because they teach other white blood cells (cells that fight cancer) to recognize specific markers on other cells in the body. Training white blood cells to recognize these specific markers for prostate cancer may help the immune system identify and attack the prostate cancer cells in the body.

Contact the Lombardi CancerLine to learn more. Phone: 202-444-4000
Email: LombardiCancerLine@gunet.georgetown.edu